Volunteer infection studies accelerate the clinical development of novel drugs against malaria [1]
Doi: 10.1016/S1473-3099(21)00722-2

Photo: Gerasimov_iStock
Abstract
Malaria-related morbidity and mortality is highest in young children and pregnant women, and WHO estimated that in 2020, 627 000 humans died of malaria, mainly from Plasmodium falciparum infections. Malaria elimination will foster economic development of affected countries and allow reallocation of around US$3·0 billion currently spent yearly for malaria control. Malaria elimination is thought to be achieved by a combination of interventions targeting the insect transmitting vector and the human host, including deployment of highly efficacious malaria drugs.
To view the full article please visit the Lancet Infectious Diseases website [2].